Dren Bio
CompanyUnited States
Dren Bio develops one asset, in phase 1 (dibotatug in aplastic anemias). Mostly antibody acting on KLRD1; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- Raised
- $446M
- 1
- Trial
- 1
- Signal
Pipeline
1Targets CD94 to deplete cytotoxic T cells and natural killer cells through antibody-dependent cellular cytotoxicity.
Phase 1, Antibody, KLRD1, aplastic anemias, bone marrow failure syndrome
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Funding rounds and grants4
- Signals2
- Similar companies2